Solution for infusions Linezolid KRKA is appointed for treatment of the infections caused by sensitive strains of anaerobic or aerobic gram-positive microorganisms including the infections which are followed by bacteremia such as:

• hospital pneumonia;
• not hospital pneumonia;
• complicated infections of skin and its structures, in particular infections against the background of diabetic foot without the accompanying osteomyelitis, the caused Staphylococcus aureus (metitsillinchuvstvitelny and metitsillinrezistentny isolates), Streptococcus pyogenes or Streptococcus agalactiae;
• uncomplicated infections of skin and its structures caused by Staphylococcus aureus (only metitsillinchuvstvitelny isolates) or Streptococcus pyogenes;
• an infection, caused by enterococci, including strains of Enterococcus faecium and faecalis, resistant to Vancomycinum.

If contagiums include gram-negative microorganisms, purpose of combination therapy is clinically shown.

Structure

active ingredient: linezolid;

1 ml 2 mg of a linezolid; 300 ml of solution for infusions contain 600 mg of a linezolid in a system;

Excipients: citrate sodium a dihydrate, citric acid, glucose monohydrate, hydrochloric acid *, sodium hydroxide *, water for injections.

in production for establishment rn solution within 4.6-5.2.

Contraindication

Known hypersensitivity to a linezolid or to any other component of drug. Linezolid does not follow will allure to the patients taking any medicaments suppressing monoamine oxidase A and B (for example fenelzin, an isocarboxazid, selegilin, moklobemid), or within two weeks after intake of such drugs.

except for cases when there is a possibility of careful observation and monitoring of arterial blood pressure, with such accompanying clinical conditions or the accompanying intake of medicaments stated below:

• uncontrollable arterial hypertension, pheochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder, sharp episodes of dizziness;
• inhibitors of the return serotonin reuptake, tricyclic antidepressants, agonists 5-HT ₁ serotonin receptors (triptanes), direct and indirect sympathomimetics (including adrenergic bronchodilators, pseudoephedrine, fenilpropanolamin), vazopressor (epinephrine, Norepinephrinum), dopaminergic connections (dopamine, Dobutaminum), pethidine or buspiron.

Patients whose treatment was begun with appointment Linezolid in solution for intravenous infusions can be transferred to

to treatment by medicaments of a linezolid in shape for oral administration. In that case selection of a dose is not required as the bioavailability of a linezolid at intake is nearly 100%.

Infusion is performed by

within 30-120 minutes.

At simultaneous administration of medicament Linezolid for intravenous injections with other medicine each medicament should be entered separately, according to the recommended dose and a route of administration of each medicine.

When using one intravenous system for consecutive input of several medicaments Linezolid for intravenous infusions should wash this system before administration of medicament with the infusion solution compatible to Linezolid and with other medicament which is administered through this system.

Compatible solutions for infusions of 0.9% chloride sodium solution for injections, 5% dextrose solution for injections, Ringera solution lactat for injections.

Feature of use

Pregnant

Linezolid should not be accepted during pregnancy, except cases when the expected advantage exceeds potential risk.

to Apply

from the first days of life.

Drivers

needs to warn patients about a possibility of development of dizziness or symptoms of a disorder of vision (see the section "Special Security Measures" and "Side reactions") during reception of a linezolid and to recommend to them not to drive the car and not to work with other mechanisms in case of the specified symptoms.

Overdose

Specific antidote.

did Not register overdose cases.

in case of overdose showed symptomatic treatment with holding actions for support of level of glomerular filtration. About 30% of the accepted dose of medicament are removed within 3 hours of a hemodialysis, but there are no data on removal of a linezolid during the procedures of peritoneal dialysis or hemoperfusion. Two primary metabolites of a linezolid are also removed by a hemodialysis.

Side effects

Most frequent side reactions which led to medicament withdrawal were a headache, diarrhea, nausea and vomiting.

Linezolid is not applied by

to the patients accepting the medicines suppressing monoamine oxidase A and B (for example, fenelzin, an isocarboxazid, selegilin, moklobemid), and within 2 weeks after their reception.

Storage conditions

to Store

in original (primary and secondary) packing for protection against effect of light at a temperature not above 30 °C.

to Store

out of children's reach.

Expiration date - 2 years.